Allogene Therapeutics reported earnings of -$ 0.15 per ALLO share on Nov 5, 2026, beating analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.15 |
| Earnings Per Share (Surprise) | -$ 0.15 ($ 0.00) |
| Last Year's EPS | -$ 0.22 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, Allogene Therapeutics beat analysts’ expectations 26 times and fell short of expectations 5 time(s). Allogene Therapeutics reported earnings per share of -$ 0.15 in the last report falling to reach an estimated EPS of -$ 0.15 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.15 | -$ 0.15 | -$ 0.19 | |
| Aug 12, 2026 | -$ 0.17 | -$ 0.13 | -$ 0.23 | |
| May 13, 2026 | -$ 0.19 | -$ 0.18 | -$ 0.28 | |
| Mar 12, 2026 | -$ 0.25 | -$ 0.17 | -$ 0.28 | |
| Nov 6, 2025 | -$ 0.23 | -$ 0.19 | -$ 0.27 | |
| Aug 13, 2025 | -$ 0.28 | -$ 0.23 | -$ 0.32 | |
| May 13, 2025 | -$ 0.28 | -$ 0.28 | -$ 0.38 | |
| Mar 13, 2025 | -$ 0.34 | -$ 0.28 | -$ 0.43 | |
| Nov 7, 2024 | -$ 0.34 | -$ 0.27 | -$ 0.37 | |
| Aug 7, 2024 | -$ 0.35 | -$ 0.32 | -$ 0.53 | |
| May 13, 2024 | -$ 0.38 | -$ 0.38 | -$ 0.68 | |
| Mar 14, 2024 | -$ 0.47 | -$ 0.43 | -$ 0.66 | |
| Nov 2, 2023 | -$ 0.53 | -$ 0.37 | -$ 0.58 | |
| Aug 2, 2023 | -$ 0.59 | -$ 0.53 | -$ 0.52 | |
| May 3, 2023 | -$ 0.63 | -$ 0.68 | -$ 0.56 | |
| Feb 28, 2023 | -$ 0.71 | -$ 0.66 | -$ 0.54 | |
| Nov 2, 2022 | -$ 0.62 | -$ 0.58 | -$ 0.57 | |
| Aug 9, 2022 | -$ 0.61 | -$ 0.52 | -$ 0.53 | |
| May 4, 2022 | -$ 0.59 | -$ 0.56 | -$ 0.25 | |
| Feb 23, 2022 | -$ 0.61 | -$ 0.54 | -$ 0.53 |
Allogene Therapeutics’s stock was trading at $ 1.19 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, ALLO’s price decreased to $ 1.04 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.15 | $ 1.19 | $ 1.04 | |
| Aug 12, 2026 | -$ 0.13 | $ 2.12 | $ 1.98 | |
| May 13, 2026 | -$ 0.18 | $ 2.30 | $ 2.14 | |
| Mar 12, 2026 | -$ 0.17 | $ 2.63 | $ 2.40 | |
| Nov 6, 2025 | -$ 0.19 | $ 1.11 | $ 1.18 | |
| Aug 13, 2025 | -$ 0.23 | $ 1.03 | $ 1.07 | |
| May 13, 2025 | -$ 0.28 | $ 1.17 | $ 0.9528 | |
| Mar 13, 2025 | -$ 0.28 | $ 2.06 | $ 1.94 | |
| Nov 7, 2024 | -$ 0.27 | $ 3.22 | $ 3.08 | |
| Aug 7, 2024 | -$ 0.32 | $ 2.55 | $ 2.36 | |
| May 13, 2024 | -$ 0.38 | $ 2.76 | $ 2.96 | |
| Mar 14, 2024 | -$ 0.43 | $ 4.88 | $ 4.66 | |
| Nov 2, 2023 | -$ 0.37 | $ 2.83 | $ 3.50 | |
| Aug 2, 2023 | -$ 0.53 | $ 4.79 | $ 5.14 | |
| May 3, 2023 | -$ 0.68 | $ 5.35 | $ 6.45 | |
| Feb 28, 2023 | -$ 0.66 | $ 6.33 | $ 6.34 | |
| Nov 2, 2022 | -$ 0.58 | $ 10.57 | $ 9.52 | |
| Aug 9, 2022 | -$ 0.52 | $ 15.96 | $ 16.20 | |
| May 4, 2022 | -$ 0.56 | $ 9.04 | $ 9.25 | |
| Feb 23, 2022 | -$ 0.54 | $ 9.72 | $ 9.25 |
Allogene Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Allogene Therapeutics missed analysts’ expectations during the last earnings period by
